Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis. - Bissonnette R; Stein Gold L; Kircik L; Simpson EL; Eichenfield LF; Browning J; Hebert AA; Alexis AF; Soong W; Piscitelli SC; Tallman AM; Rubenstein DS; et al. (Journal of the American Academy of Dermatology, 2025)